Metabolism and toxicity of two new benzodiazepine-type antileishmanial agents in hepatocytes and macrophages by Duong Thi, M.D. et al.
Strathprints Institutional Repository
Duong Thi, M.D. and Clarke, R. and Mackay, S.P. and Mullen, A.B. and Tettey, J.N.A. and Grant,
M.H. (2007) Metabolism and toxicity of two new benzodiazepine-type antileishmanial agents in
hepatocytes and macrophages. Toxicology, 231 (2-3). pp. 104-105. ISSN 0300-483X
Strathprints is designed to allow users to access the research output of the University of Strathclyde.
Copyright c© and Moral Rights for the papers on this site are retained by the individual authors
and/or other copyright owners. You may not engage in further distribution of the material for any
profitmaking activities or any commercial gain. You may freely distribute both the url (http://
strathprints.strath.ac.uk/) and the content of this paper for research or study, educational, or
not-for-profit purposes without prior permission or charge.
Any correspondence concerning this service should be sent to Strathprints administrator:
mailto:strathprints@strath.ac.uk
http://strathprints.strath.ac.uk/
Toxicology 231 (2007) 104–119
BTS Abstracts Autumn 2006, Poster Abstracts
Available online 12 November 2006
Metabolism and toxicity of two new benzodiazepine-
type antileishmanial agents in hepatocytes and
macrophages
M. Dao Duong Thi 1, Rachel L. Clark 1, Simon P.
Mackay 1, Alex B. Mullen 1, Justice N.A. Tettey 1, M.
Helen Grant 2,
E-mail address: m.h.grant@strath.ac.uk (M.H. Grant).
1 Department of Pharmaceutical Sciences, University
of Strathclyde, Glasgow G4 0NW, United Kingdom
2 Bioengineering Unit, University of Strathclyde, Glas-
gow G4 0NW, United Kingdom
With increasing reports of resistance of Leishmania
to antimonials (Thakur et al., 2004) and other traditional
antileishmanial drugs, the need for the discovery of new
antileishmanial agents is rising. In an attempt to find
new antileishmanial agents, two new benzodiazepine
(BNZ) analogues (7-chloro-4-(cyclohexylmethyl)-1-
methyl-3,4-dihydro-1H-1,4-benodiazepine-2,5-dione
(BNZ-1) and 4-(cyclohexylmethyl)-1-methyl-3,4-
dihydro-1H-1,4-benzodiazepine-2,5-dione (BNZ-2))
were synthesised, and found to be effective against
leishmaniasis in mice. This study investigates the
metabolism of these two drugs together with the pro-
totype BNZ, flurazepam (FZP), using rat hepatocytes,
and investigates their interaction with glutathione in
macrophages.
Hepatocytes (>80% viability by Trypan Blue exclu-
sion isolated by liver perfusion with collagenase) were
prepared from male Sprague–Dawley rats (200–250 g).
Drugs (100M) were incubated with 2 × 106 viable
cells/ml in Krebs-Hepes buffer, pH 7.4, in rotating round
bottomed flasks under an atmosphere of 95% O2/5%
CO2, at 37 ◦C for 3 h, and timed samples taken for
metabolite measurement. Samples were extracted twice
with ethyl acetate at pH 10, the combined organic phases
evaporated to dryness and stored at −20 ◦C until anal-
ysis. Metabolites were separated by HPLC using an
ACE C18 column (50 mm × 3.0 mm i.d., 5m packing),
and a solvent gradient consisting of 0.1% formic acid:
acetonitrile (starting composition 95:5%, and composi-
tion after 25 min 65:35% for FZP and 70:30% for both
BNZ 1 and 2). Flow rate was 0.5 ml/min, and detec-
tion was at 230 nm. Identification of the metabolites was
by mass spectrometry with both positive and negative
ion electronspray ionization. The effects of 24 h expo-
sure to the compounds (100M) was investigated in the
macrophage cell line J774.1 in terms of reduced glu-
tathione content (GSH) and the activity of glutathione
reductase (GR).
There was no evidence of significant cytotoxicity
with any of the compounds at the concentration used.
FZP (m/z 388) was metabolised by dealkylation of
the two N-1 ethyl substituents (m/z 360 and m/z 332),
followed by hydroxylation on the BNZ ring. There
was no evidence for either N- or O-glucuronidation
of the resulting metabolites. BNZ-1 (m/z 321) was
metabolised by N-demethylation (m/z 307) followed by
hydroxylation (m/z 323), mono- and di-hydroxylation of
the parent (m/z 337 and m/z 353) and by glucuronidation
of the mono-hydroxylated metabolite (m/z 513). BNZ-2
(m/z 287) was transformed by N-demethylation (m/z
273) and hydroxylation of the parent (m/z 303), with the
latter further metabolised by O-glucuronidation (m/z
479). In addition, the hydroxylated N-demethylated
product (m/z 289) was also formed. Macrophages did
not produce detectable metabolism of any of the drugs.
All the drugs depleted macrophage GSH significantly
(p < 0.05 by ANOVA followed by Dunnett’s test) with
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BNZ-1 and BNZ-2 causing greater depletion than FZP
(40.6 ± 4.0 and 45.8 ± 8.4, respectively, compared
with 55.5 ± 4.9 nmol/mg protein with FZP, n = 3).
Control macrophage GSH was 74.1 ± 6.6 nmol/mg
protein. The depletion in GSH was not due to inhibition
of GR: only FZP caused a significant decrease in
macrophage GR activity (28.0 ± 5.9 compared with
42.1 ± 8.0 nmol/ml/min in control cells, p < 0.05 by
ANOVA followed by Dunnett’s test, n = 3).
The marked depletion of macrophage GSH indi-
cates a potential toxic interaction in mammalian cells.
The new BNZ analogues were rapidly metabolised
by hepatocytes, producing N-dealkylated and multiple
hydroxylated phase I metabolites, followed by glu-
curonidation. This rapid metabolism may limit the
therapeutic effect of BNZ 1 and 2 if their metabolites
are inactive against leishmaniasis and suggest the need
to optimise these lead structures further to obtain com-
pounds with reduced rates and extent of metabolism.
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Cobalt chromium (CoCr) alloy and stainless steel are
widely used in orthopaedic implants. Cr(VI) is known
to be released when metals corrode in vivo (Milosˇev et
al., 2005) and may be toxic to local cells like osteoblasts
and macrophages. Ning and Grant (2000) have demon-
strated the acute toxicity of Cr(VI) to immortalised rat
osteoblasts and shown the involvement of reduced glu-
tathione (GSH) and glutathione reductase (GRd) in the
interaction. The aim of this study was to investigate the
chronic effects of exposure to clinically relevant Cr(VI)
concentrations on the human monocyte cell line (U937)
over 4 weeks in vitro.
U937 cells (1.5 × 106 per ml) were exposed to 0, 0.05,
0.1 and 0.5M Cr(VI) (chromium oxide) for 4 weeks.
Protein and GSH content, GRd expression (SDS-PAGE
followed by Western blotting) and activity (Carlberg and
Mannervik, 1985) were measured. The measured param-
eters for cells exposed to 0.5M Cr(VI) are displayed
below in Fig. 1. Lower concentrations of Cr(VI) did not
have a significant effect on the parameters measured.
The cells responded with a steady decline in protein
content from 67.45 ± 1.12 to 23.35 ± 0.97% of con-
trol level between weeks 1 and 4 indicating a loss of
Fig. 1. Protein (A), GSH content (B), GRd activity (C) and GRd expression (D) in cells exposed to 0.5M Cr(VI). Results are expressed as a %
of control cultures in the absence of Cr(VI) and are corrected for protein content; mean ± S.E.M., n = 3 separate experiments, *P < 0.05 ANOVA,
followed by Dunnett’s multiple comparison test.
